CD8A and B-cell non-Hodgkin lymphoma: However, by using a chimeric mouse/human IgG DNA vaccine delivered by intramuscular injection, it was shown that protection in the 38C13 murine B cell lymphoma model was not impaired by CD4+/CD8+ T cell depletion (Syrengelas and Levy, 1999).